Increasing work-place healthiness with the probiotic Lactobacillus reuteri: a randomised, double-blind placebo-controlled study
- PMID:16274475
- PMCID: PMC1298318
- DOI: 10.1186/1476-069X-4-25
Increasing work-place healthiness with the probiotic Lactobacillus reuteri: a randomised, double-blind placebo-controlled study
Abstract
Background: Short term illnesses, usually caused by respiratory or gastrointestinal diseases are disruptive to productivity and there is relatively little focus on preventative measures. This study examined the effect of the probiotic Lactobacillus reuteri protectis (ATCC55730) on its ability to improve work-place healthiness by reducing short term sick-leave caused by respiratory or gastrointestinal infections.
Methods: 262 employees at TetraPak in Sweden (day-workers and three-shift-workers) that were healthy at study start were randomised in a double-blind fashion to receive either a daily dose of 108 Colony Forming Units of L. reuteri or placebo for 80 days. The study products were administered with a drinking straw. 181 subjects complied with the study protocol, 94 were randomised to receive L. reuteri and 87 received placebo.
Results: In the placebo group 26.4% reported sick-leave for the defined causes during the study as compared with 10.6% in the L. reuteri group (p < 0.01). The frequency of sick-days was 0.9% in the placebo group and 0.4% in the L. reuteri group (p < 0.01). Among the 53 shift-workers, 33% in the placebo group reported sick during the study period as compared with none in the L. reuteri group(p < 0.005).
Figures
Similar articles
- Survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus GG in the human gastrointestinal tract with daily consumption of a low-fat probiotic spread.Dommels YE, Kemperman RA, Zebregs YE, Draaisma RB, Jol A, Wolvers DA, Vaughan EE, Albers R.Dommels YE, et al.Appl Environ Microbiol. 2009 Oct;75(19):6198-204. doi: 10.1128/AEM.01054-09. Epub 2009 Aug 14.Appl Environ Microbiol. 2009.PMID:19684171Free PMC article.Clinical Trial.
- Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study.Francavilla R, Polimeno L, Demichina A, Maurogiovanni G, Principi B, Scaccianoce G, Ierardi E, Russo F, Riezzo G, Di Leo A, Cavallo L, Francavilla A, Versalovic J.Francavilla R, et al.J Clin Gastroenterol. 2014 May-Jun;48(5):407-13. doi: 10.1097/MCG.0000000000000007.J Clin Gastroenterol. 2014.PMID:24296423Clinical Trial.
- Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial.Sung V, Hiscock H, Tang ML, Mensah FK, Nation ML, Satzke C, Heine RG, Stock A, Barr RG, Wake M.Sung V, et al.BMJ. 2014 Apr 1;348:g2107. doi: 10.1136/bmj.g2107.BMJ. 2014.PMID:24690625Free PMC article.Clinical Trial.
- Lactobacillus reuteri to Treat Infant Colic: A Meta-analysis.Sung V, D'Amico F, Cabana MD, Chau K, Koren G, Savino F, Szajewska H, Deshpande G, Dupont C, Indrio F, Mentula S, Partty A, Tancredi D.Sung V, et al.Pediatrics. 2018 Jan;141(1):e20171811. doi: 10.1542/peds.2017-1811.Pediatrics. 2018.PMID:29279326Review.
- Lactobacillus reuteri for chronic periodontitis: focus on underlying mechanisms and future perspectives.Zhou K, Xie J, Su Y, Fang J.Zhou K, et al.Biotechnol Genet Eng Rev. 2024 Apr;40(1):381-408. doi: 10.1080/02648725.2023.2183617. Epub 2023 Mar 1.Biotechnol Genet Eng Rev. 2024.PMID:36856460Review.
Cited by
- Probiotic Lactobacillus reuteri ameliorates disease due to enterohemorrhagic Escherichia coli in germfree mice.Eaton KA, Honkala A, Auchtung TA, Britton RA.Eaton KA, et al.Infect Immun. 2011 Jan;79(1):185-91. doi: 10.1128/IAI.00880-10. Epub 2010 Oct 25.Infect Immun. 2011.PMID:20974822Free PMC article.
- The microbiome of the built environment and mental health.Hoisington AJ, Brenner LA, Kinney KA, Postolache TT, Lowry CA.Hoisington AJ, et al.Microbiome. 2015 Dec 17;3:60. doi: 10.1186/s40168-015-0127-0.Microbiome. 2015.PMID:26674771Free PMC article.Review.
- Genomic and genetic characterization of the bile stress response of probiotic Lactobacillus reuteri ATCC 55730.Whitehead K, Versalovic J, Roos S, Britton RA.Whitehead K, et al.Appl Environ Microbiol. 2008 Mar;74(6):1812-9. doi: 10.1128/AEM.02259-07. Epub 2008 Feb 1.Appl Environ Microbiol. 2008.PMID:18245259Free PMC article.
- Probiotic Formulations: Application and Status as Pharmaceuticals-A Review.Sreeja V, Prajapati JB.Sreeja V, et al.Probiotics Antimicrob Proteins. 2013 Jun;5(2):81-91. doi: 10.1007/s12602-013-9126-2.Probiotics Antimicrob Proteins. 2013.PMID:26782733
- The Microbiota, Immunoregulation, and Mental Health: Implications for Public Health.Lowry CA, Smith DG, Siebler PH, Schmidt D, Stamper CE, Hassell JE Jr, Yamashita PS, Fox JH, Reber SO, Brenner LA, Hoisington AJ, Postolache TT, Kinney KA, Marciani D, Hernandez M, Hemmings SM, Malan-Muller S, Wright KP, Knight R, Raison CL, Rook GA.Lowry CA, et al.Curr Environ Health Rep. 2016 Sep;3(3):270-86. doi: 10.1007/s40572-016-0100-5.Curr Environ Health Rep. 2016.PMID:27436048Free PMC article.Review.
References
- Confederation of Swedish Enterprise Facts about Health Insurance and Paid Sick Leave. 2005.http://www.svensktnaringsliv.se/Index.asp?PN=228625&ID=1029495
- Jeding K, Hägg GM, Marklund s, Nygren Å, Theorell T, Vingård E. Ett friskt arbetsliv. Arbete och hälsa vetenskaplig skriftserie. 1999;22:1–88.
- Mohren DCL, Jansen NWH, Kant I, Galama J, van den Brandt PA, Swaen GMH. Prevalence of common infections among employees in different work schedules. JOEM. 2002;44:1003–1011. - PubMed
- Cummings JH, Antoine J-M, Azpiroz F, Bourdet-Sicard R, Brandtzaeg P, Calder PC, Gibson GR, Guarner F, Isolauri E, Pannemans D, Shortt C, Tuijtelaars S, Watzl B. PASSCLAIM – Gut health and Immunity. Eur J Nutr. 2004;43:118–173. - PubMed
- Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: Comparison of two probiotic agents. Pediatrics. 2005;115:5–9. - PubMed
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources